Bruno Vision Care, a vision health technology firm, has secured marketing authorisation from the US Food and Drug Administration (FDA) for its Deseyne daily disposable contact lens.
According to Bruno Vision Care, the lenses feature the company’s proprietary vifilcon C lens material and FusionTechnology-controlled delivery system. Both these components were approved by the FDA in October 2024.
The latest FDA’s approval covers both the lens composition and its integrated release mechanism. Deseyne lenses are designed to gradually deliver specific compounds to the eye’s surface during wear, using a system that responds to natural eye movements and temperature.
The approved technology embeds bioactive ingredients, referred to as Lachryceuticals, directly into the lens matrix during production. These substances, including amino acids, vitamins, and polysaccharides, are released steadily throughout the day.
The process is activated by a combination of eyelid pressure, blinking, and body heat, aiming to ensure their sustained availability on the eye’s anterior segment.
FusionTechnology combines two biopolymers, which include hyaluronic acid and tamarind seed polysaccharides. These form a natural copolymer that mimics the properties of human tears.
This mixture is gradually released during lens wear, intended to maintain tear film stability and ocular surface hydration.
Bruno Vision Care CEO Eddie Catalfamo said: “Deseyne isn’t just another contact lens, it defines a completely new category by incorporating a patented delivery system directly into the lens.
“With our patented FusionTechnology proprietary manufacturing process and the novel vifilcon C material, we’re setting a new standard in vision health. The result is a lens that allows more people to wear contacts comfortably, provides existing wearers with greater hydration and clearer vision, and makes fitting easier for eye care professionals.”
Bruno Vision Care has confirmed that Deseyne contact lenses will be launched in the US in the final quarter of 2025.
